Survival benefit from first docetaxel treatment for cabazitaxel plus prednisone compared with mitoxantrone plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) enrolled in the TROPIC trial.

被引：1
|
作者：
Sartor, A. O.
Oudard, S.
Ozguroglu, M.
Hansen, S.
Machiels, J. H.
Shen, L.
De Bono, J. S.
机构：
[1] Tulane Sch Med, New Orleans, LA USA
[2] George Pompidou European Hosp, Paris, France
[3] Istanbul Univ, Cerrahpasa Med Fac, Dept Med Oncol, Istanbul, Turkey
[4] Odense Univ Hosp, DK-5000 Odense, Denmark
[5] Catholic Univ Louvain, Ctr Canc, Clin Univ St Luc, B-1200 Brussels, Belgium
[6] Sanofi Aventis, Malvern, PA USA
[7] Inst Canc Res, Sutton, Surrey, England
[8] Royal Marsden Hosp, Sutton, Surrey, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.4525
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4525
引用
收藏
页数：1
相关论文
共 50 条
  • [11] Cabazitaxel or mitoxantrone with prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: Estimating mean overall survival (OS) for health economic analyses from a phase III trial (TROPIC)
    Oudard, S.
    Joulain, F.
    De Geer, A.
    Sartor, A. O.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [12] REAL-WORLD USE OF CABAZITAXEL PLUS PREDNISONE IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (mCRPC) PREVIOUSLY TREATED WITH DOCETAXEL: REGIONAL ANALYSIS
    Parente, P.
    Malik, Z.
    di Lorenzo, G.
    Bracarda, S.
    Ardavanis, A.
    Basaran, M.
    de Schultz, W.
    Saad, F.
    van Oort, I.
    Gerritsen, W. R.
    Anton Aparicio, L. M.
    Matus, G.
    Hitier, S.
    Heidenreich, A.
    Bahl, A.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2015, 11 : 62 - 62
  • [13] Abiraterone plus prednisone improves survival in metastatic castration-resistant prostate cancer
    Tagawa, Scott T.
    Beltran, Himisha
    ASIAN JOURNAL OF ANDROLOGY, 2011, 13 (06) : 785 - 786
  • [14] Comparison of two doses of cabazitaxel plus prednisone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with a docetaxel (D)-containing regimen
    Eisenberger, Mario A.
    Hardy-Bessard, Anne-Claire
    Mourey, Loic
    Mainwaring, Paul N.
    Ford, Daniel
    Shapiro, Jeremy David
    Carles, Joan
    Ng, Siobhan
    Gil, Thierry
    Alekseev, Boris
    Ivanov, Sergey
    Facchini, Thomas
    Legouffe, Eric
    Apolikhin, Oleg
    Pandha, Hardev S.
    Beeker, Aart
    Karyakin, Oleg
    Zhang, Wendy
    Chadjaa, Mustapha
    De Bono, Johann Sebastian
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [15] Effect of G-CSF prophylaxis on the occurrence of neutropenia in men receiving cabazitaxel plus prednisone for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in the TROPIC study
    Ozguroglu, M.
    Oudard, S.
    Sartor, A. O.
    Hansen, S.
    Machiels, J. H.
    Shen, L.
    De Bono, J. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [16] Phase II trial of bevacizumab and lenalidomide with docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC)
    Adesunloye, Bamidele
    Huang, Xuan
    Ning, Yangmin M.
    Madan, Ravi A.
    Gulley, James L.
    Beatson, Melony
    Kluetz, Paul Gustav
    Adelberg, David
    Arlen, Philip M.
    Parnes, Howard L.
    Mulquin, Marcia
    Steinberg, Seth M.
    Wright, John Joseph
    Trepel, Jane B.
    Dawson, Nancy Ann
    Chen, Clara
    Apolo, Andrea Borghese
    Figg, William Douglas
    Dahut, William L.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [17] A Randomised Phase II Trial Comparing Docetaxel Plus Prednisone with Docetaxel Plus Prednisone Plus Low-Dose Cyclophosphamide in Castration-Resistant Prostate Cancer
    Porsch, Markus
    Ulrich, Matthias
    Wendler, Johann Jakob
    Liehr, Uwe-Bernd
    Reiher, Frank
    Janitzky, Andreas
    Baumunk, Daniel
    Schindele, Daniel
    Seseke, Florian
    Lux, Anke
    Schostak, Martin
    CHEMOTHERAPY, 2014, 60 (02) : 129 - 134
  • [18] Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial (vol 376, pg 1147, 2010)
    Bono, J. S.
    Oudard, S.
    Ozguroglu, M.
    LANCET, 2011, 377 (9767): : 720 - 720
  • [19] Switch from abiraterone plus prednisone to abiraterone plus dexamethasone after PSA progression under abiraterone plus prednisone in asymptomatic metastatic castration-resistant prostate cancer (mCRPC) patients
    Fenioux, C.
    Louvet, C.
    Prapotnich, D.
    Ropert, S.
    Barret, E.
    Sanchez-Salas, R.
    Mombet, A.
    Cathala, N.
    Poullennec, B.
    Joulia, M-L.
    Ung, M.
    Cathelineau, X.
    Bennamoun, M.
    ANNALS OF ONCOLOGY, 2016, 27
  • [20] A phase II randomised trial of abiraterone acetate plus prednisone in combination with docetaxel or docetaxel plus prednisone after disease progression to abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer: The ABIDO-SOGUG trial
    Climent, Miguel A.
    Font, Albert
    Duran, Ignacio
    Puente, Javier
    Mendez-Vidal, Maria Jose
    Isabel Saez, Maria
    Lobera, Carmen Santander
    Arranz Arija, Jose Angel
    Gonzalez-Del-Alba, Aranzazu
    Sanchez-Hernandez, Alfredo
    Juan Fita, Maria Jose
    Esteban, Emilio
    Alonso-Gordoa, Teresa
    Mellado Gonzalez, Begona
    Maroto, Pablo
    Lazaro-Quintela, Martin
    Cassinello-Espinosa, Javier
    Perez-Valderrama, Begona
    Garcias, Carmen
    Castellano, Daniel
    EUROPEAN JOURNAL OF CANCER, 2022, 175 : 110 - 119
12345